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MeBACKGROUND Surgical mitral valve repair (SMVR) remains the gold standard for severe degenerative mitral regur-
gitation (DMR). However, the results with transcatheter mitral valve repair (TMVR) in prohibitive-risk DMR patients have
not been previously reported.
OBJECTIVES This study aimed to evaluate treatment of mitral regurgitation (MR) in patients with severe
DMR at prohibitive surgical risk undergoing TMVR.
METHODS A prohibitive-risk DMR cohort was identiﬁed by a multidisciplinary heart team that retrospectively evaluated
high-risk DMR patients enrolled in the EVEREST (Endovascular Valve Edge-to-Edge Repair Study) II studies.
RESULTS A total of 141 high-risk DMR patients were consecutively enrolled; 127 of these patients were retro-
spectively identiﬁed as meeting the deﬁnition of prohibitive risk and had 1-year follow-up (median: 1.47 years)
available. Patients were elderly (mean age: 82.4 years), severely symptomatic (87% New York Heart Association class
III/IV), and at prohibitive surgical risk (STS score: 13.2  7.3%). TMVR (MitraClip) was successfully performed in
95.3%; hospital stay was 2.9  3.1 days. Major adverse events at 30 days included death in 6.3%, myocardial
infarction in 0.8%, and stroke in 2.4%. Through 1 year, there were a total of 30 deaths (23.6%), with no survival
difference between patients discharged with MR #1þ or MR 2þ. At 1 year, the majority of surviving patients (82.9%)
remained MR #2þ at 1 year, and 86.9% were in New York Heart Association functional class I or II. Left ventricular
end-diastolic volume decreased (from 125.1  40.1 ml to 108.5  37.9 ml; p < 0.0001 [n ¼ 69 survivors with paired
data]). SF-36 quality-of-life scores improved and hospitalizations for heart failure were reduced in patients whose MR
was reduced.
CONCLUSIONS TMVR in prohibitive surgical risk patients is associated with safety and good clinical outcomes,
including decreases in rehospitalization, functional improvements, and favorable ventricular remodeling, at 1 year.
(Real World Expanded Multi-center Study of the MitraClip System [REALISM]; NCT01931956)
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183T he most common cause of mitral regurgita-tion (MR) in the United States is primary ordegenerative mitral valve (MV) disease,
which results from congenital or degenerative
changes of the valve. Degenerative MR (DMR) initi-
ates a cascade of events, which when left untreated,
eventually develop into heart failure (HF) and death.
Surgical mitral valve repair (SMVR) remains the gold
standard for treatment of severe MR, with the stron-
gest indications (Class I and IIa) for patients withSEE PAGE 193
MV = mitral valve
NYHA = New York Heart
Association
PCS = Physical Component
Summary
QoL = quality of life
STS = Society of Thoracic
Surgery
SMVR = surgical mitral valve
repair
TMVR = transcatheter mitral
valve repairDMR (1). However, DMR patients who have a prohib-
itive risk of surgical mortality have a poor prognosis,
as no medical therapy has been found to improve out-
comes. The transcatheter mitral valve repair (TMVR)
device (MitraClip, Abbott Vascular, Santa Clara, Cali-
fornia) has shown promise in reducing MR severity
and improving clinical and functional outcomes and
quality of life (QoL) in patients with severe MR (2).
The objective of this study was to evaluate the rela-
tionship between reduction of MR with TMVR and
improvement in functional status in patients with se-
vere DMR at prohibitive surgical risk.METHODS
PROPOSED DEFINITION OF PROHIBITIVE SURGICAL
RISK. Prohibitive risk includes patients with a
Society of Thoracic Surgery (STS) predicted risk of
mortality for MV replacement of $8% (STS calculator
version 2.73), or if the patient has factors for prohibi-
tive surgical risk not included in the STS risk calculator.
For purposes of this study, prohibitive risk for
surgical repair of DMR is deﬁned as the presence of
one or more of the following documented surgical
risk factors: 1) STS predicted risk of 30-day mortality
of $8% for MV replacement; 2) porcelain aorta or
extensively calciﬁed ascending aorta; 3) frailty
(assessed by 2 or more indices); 4) hostile chest; 5)
severe liver disease/cirrhosis (Model of End-stage
Liver Disease (MELD) score >12); 6) severe pulmo-
nary hypertension (systolic pulmonary artery pressure
more than two-thirds systemic pressure); 7) unusualgrants from Abbott, Edwards Lifesciences, Gilead Sciences, and the Am
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ventricular dysfunction with severe
tricuspid regurgitation, chemotherapy for
malignancy, major bleeding diathesis,
immobility, Acquired Immune Deﬁciency
Syndrome, severe dementia, high risk of
aspiration, and internal mammary artery
grafts at high risk of injury in a graft-
dependent patient.
DETERM INAT ION OF PROH IB I T I VE
SURG ICAL R I SK AND MV ANATOM IC
SU I TAB I L I TY. From 2003 to 2012, 544
patients with severe ($3þ) DMR were
prospectively enrolled in EVEREST I
(Endovascular Valve Edge-to-Edge Repair
Study), EVEREST II RCT, EVEREST II High
Risk Registry, and REALISM (Real World Ex-
panded Multi-center Study of the MitraClip
System) continued-access registry (which in-
cluded both a non–high-risk arm and a high-
risk arm). Transthoracic echocardiography
and transesophageal echocardiography screening was
used to establish protocol-based eligibility for the
TMVR procedure (2). Those patients enrolled in the
EVEREST II RCT and in the early part of the REALISM
studies were of low to moderate surgical risk. How-
ever, patients enrolled in the EVEREST II High Risk
study (enrollment: February 14, 2007, through
January 30, 2008) and the later REALISM continued-
access registry (enrollment began January 22, 2009,
and is ongoing) were at high surgical risk; pooling of
data from these 2 studies was pre-speciﬁed in the
latter protocol. Selection criteria for both studies
were identical. Of the 544 patients with severe DMR,
141 constituted a consecutively enrolled high surgical
risk group. The case ﬁles for each of these 141 patients
from these studies were retrospectively reviewed for
prohibitive-risk status by a team of physicians,
including 2 experienced mitral valve surgeons and 1
experienced mitral valve cardiologist. For inclusion
in the current cohort, all 3 physicians had to concur
that a patient met the pre-speciﬁed deﬁnition of
prohibitive risk. After enrollment, MR severity
was graded by the independent Echocardiographicerican Heart Association (Mid-Atlantic Afﬁliate).
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184Core Laboratory (University of California, San Fran-
cisco, California, orMedStar Health Research Institute,
Washington, DC) at baseline and all follow-up
visits, following the American Society of Echo-
cardiography criteria (3).
COMPOSITION OF PROHIBITIVE-RISK DMR COHORT.
The retrospective review identiﬁed 127 of the 141
high-risk DMR patients who met the deﬁnition of
prohibitive risk (treated between 2003 and 2012
at 34 investigational sites) with 1-year follow-
up (median follow-up: 1.47 years). The resulting
prohibitive-risk DMR cohort includes 25 patients
from the EVEREST II High Risk Registry, 98 patients
from the high-risk arm of the REALISM continued-
access registry, and 4 patients treated under
“compassionate use” who met the deﬁnition of pro-
hibitive risk and all MV anatomic criteria for eligi-
bility. Patients were enrolled under historical STS
versions 2.52 and 2.61 in the High Risk Registry and
version 2.61 in the high-risk arm of REALISM. For
consistency in reporting on the retrospectively iden-
tiﬁed prohibitive-risk DMR cohort, all STS scores were
recalculated using the most current version of the STS
calculator (version 2.73), and all results are reported
using this version.
TMVR PROCEDURE. The TMVR procedure was per-
formed under general anesthesia, via echocardio-
graphic and ﬂuoroscopic guidance as described in a
prior publication (2).
STUDY PROCEDURES. The ECLmeasuredMR severity
and LV size at baseline, discharge, and 12 months. New
York Heart Association (NYHA) functional class was
assessed at baseline, 30 days, and 12 months. The
SF-36 QoL questionnaire (4) was administered at
baseline, 30 days, and 12 months. Patients in the high-
risk arm of the REALISM continued-access registry
also completed the SF-36 QoL questionnaires at
6 months. HF hospitalizations 12 months prior to and
following the TMVR procedure were recorded; length
of follow-up post-TMVR was adjusted for in the anal-
ysis. An independent clinical events committee adju-
dicated major adverse events through 1 year.
STATISTICAL ANALYSIS. Continuous data are sum-
marized as mean  SD, and paired comparisons are
performed using the paired t test. The Kaplan-Meier
method was used for survival analysis. Pairwise
comparisons of survival by discharge MR were per-
formed using log-rank tests. SF-36 surveys were
scored using standard methods. SF-36 summary
scores are reported using the norm-based scoring
(population mean: 50; population standard deviation:
10; higher ¼ better), while SF-36 subscales arereported according to their original 0–100 scales
(higher ¼ better). Pairwise comparisons using the
chi-square test were performed on 2-sample pro-
portions to assess the relationship between discharge
MR severity and NYHA functional class at 1 year. The
rate of HF hospitalization is estimated and evaluated
using a Poisson regression model, with length of
follow-up post-discharge as an offset. In all analyses, a
p value <0.05 is considered statistically signiﬁcant.
RESULTS
BASELINE CHARACTERISTICS. Table 1 shows base-
line demographics and comorbidities for the
prohibitive-risk DMR cohort.
The patients had poor functional status: 86.6%
were NYHA class III/IV at baseline. As expected, SF-36
QoL scores were well below population norms.
Measures of physical function in particular were
markedly reduced: the mean Physical Component
Summary (PCS) score was 32.0 points at baseline—
nearly a full SD below the age-adjusted (age$75 years)
U.S. norm of 39.9 (5). Likewise, the mean Mental
Component Summary (MCS) score of 46.1 was below
the age-adjusted population norm of 50.2 for the MCS
score.
The reasons for prohibitive risk are summarized in
Table 2. A majority of patients (78 of 127 [61.4%])
presented with more than 1 prohibitive risk factor.
PROCEDURAL RESULTS. The mean procedure time,
deﬁned as the start time of the trans-septal cathe-
terization to the time the steerable guide catheter was
removed, was 157  81 min, or approximately 2.5 h.
The mean ﬂuoroscopy duration was 46  26 min.
There were no intraprocedural deaths.
The TMVR device was implanted successfully
in 95.3% of patients (121 of 127). Fifty-six patients
(44.1%) received 1 TMVR, and 65 patients (51.2%)
received 2 TMVR devices. Six patients (4.7%) did not
have a TMVR device implanted. Four of the 6 patients
did not receive the device due to technical reasons,
including an inability to adequately reduce MR
(n ¼ 1), inadequate MV area (n ¼ 1), an inability to
place the delivery catheter in the right atrium due to
tortuous anatomy (severe scoliosis) (n ¼ 1), and the
observation of right atrial thrombus noted on intra-
procedural TEE (n ¼ 1). The remaining 2 patients did
not receive a device due to complications that
occurred during the procedure: trans-septal compli-
cation resulting in cardiac tamponade (n ¼ 1) and
hemodynamic instability (n ¼ 1). Of the 6 patients
who did not receive a device, 1 patient underwent
MV surgery 26 days after the TMVR attempt and
TABLE 1 Baseline Demographics and Comorbidities in
Prohibitive-Risk DMR Cohort (N ¼ 127)*
Age (yrs) 82.4  8.7
>75 yrs 83.5% (106/127)
Sex
Female 44.9% (57/127)
Male 55.1% (70/127)
Comorbidities
Congestive heart failure 98.4% (125/127)
Hypertension 88.2% (112/127)
Coronary artery disease 72.8% (91/125)
Atrial ﬁbrillation history 70.5% (86/122)
Angina 39.3% (46/117)
COPD 31.5% (40/127)
Diabetes 29.9% (38/127)
Moderate to severe renal disease 28.3% (36/127)
Prior myocardial infarction 24.4% (31/127)
Cardiomyopathy 23.6% (30/127)
Cerebrovascular disease history 18.9% (24/127)
Peripheral vascular disease 15.0% (19/127)
Prior stroke 10.2% (13/127)
Treatment history
Previous cardiovascular surgery 48.0% (61/127)
Previous CABG surgery 40.9% (52/127)
Previous PCI 33.3% (42/126)
Cardiac rhythm device implant
Pacemaker 21.1% (26/123)
ICD 7.3% (9/123)
NYHA functional class
I 2.4% (3/127)
II 11.0% (14/127)
III 63.8% (81/127)
IV 22.8% (29/127)
STS replacement mortality risk (%)† 13.2  7.3 (127)
Risk $8% 79.5% (101/127)
LV function
LV ejection fraction (%) 60.6  9.5 (112)
LV internal diameter, systole (cm) 3.4  0.8 (113)
LV end-diastolic volume (ml) 127.0  40.5 (112)
Quality of life
SF-36 PCS score 32.0  8.7 (121)
SF-36 MCS score 46.1  12.5 (121)
Values are mean  SD (N) or % (n/N). *Sample sizes or denominators <N reﬂect
missing data. †Scores were recalculated by the sponsor using the STS Calculator
version 2.73 (http://riskcalc.sts.org/STSWebRiskCalc273).
CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary
disease; DMR¼ degenerative mitral regurgitation. ICD¼ implantable cardioverter-
deﬁbrillator; LV ¼ left ventricular; MCS ¼ Mental Component Summary; NYHA ¼
New York Heart Association; PCI ¼ percutaneous intervention; PCS ¼ Physical
Component Summary; SF-36 ¼ 36-item Short Form Health Survey; STS ¼ Society
of Thoracic Surgery.
TABLE 2 Prohibitive Surgical Risk Factors in This
Prohibitive-Risk DMR Cohort (N ¼ 127)*
STS mortality risk score $8% 101 (79.5%)
Risk factors in patients with STS mortality
risk score <8% not captured in
the STS calculator
Porcelain aorta 8 (6.3%)
Hostile chest 5 (3.9%)
Severe liver disease or cirrhosis 4 (3.1%)
Severe pulmonary hypertension 3 (2.4%)
Frailty 2 (1.6%)
Unusual extenuating circumstance
High risk of aspiration 4 (3.1%)
IMA at high risk of injury 4 (3.1%)
Major bleeding diathesis 2 (1.6%)
Severe dementia 2 (1.6%)
AIDS 1 (0.8%)
Chemotherapy for malignancy 1 (0.8%)
Immobility 1 (0.8%)
Values are n (%). *Nonhierarchical listing; patients may present at baseline with
more than 1 prohibitive risk factor.
IMA ¼ internal mammary artery; STS ¼ Society of Thoracic Surgery.
TABLE 3 Safety Outcomes in Prohibitive-Risk DMR Cohort
(N ¼ 127)
Description of Event 30 Days 12 Months
Major bleeding complications 12.6% (16/127) 15.7% (20/127)
Death* 6.3% (8/127) 23.6% (30/127)
Major vascular complications 5.5% (7/127) 7.1% (9/127)
Ventilation >48 h* 3.1% (4/127) 4.7% (6/127)
Stroke* 2.4% (3/127) 2.4% (3/127)
Renal failure* 1.6% (2/127) 3.9% (5/127)
Atrial septal defect 1.6% (2/127) 2.4% (3/127)
Noncerebral thromboembolism 1.6% (2/127) 1.6% (2/127)
GI complication requiring surgery* 0.8% (1/127) 2.4% (3/127)
Myocardial infarction* 0.8% (1/127) 0.8% (1/127)
Nonelective cardiovascular surgery
for adverse events*
0.8% (1/127) 0.8% (1/127)
Mitral valve stenosis 0 2.4% (3/127)
Heart block/other arrhythmia
requiring permanent pacemaker
0 1.6% (2/127)
New onset of permanent AF* 0 0
Values are % (n/N). Major bleeding complications, deﬁned as procedure-related
bleeding requiring transfusions of at least 2 units or surgery, occurred at a rate
of 12.6% at 30 days. The majority of bleeding events required transfusions rather
than surgery. *Clinical Event Committee adjudicated.
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185subsequently died on day 110. Three additional
patients died without further intervention for MR, at
days 9, 25, and 128. The remaining 2 patients with-
drew from the study without further intervention
for DMR.
SAFETY OUTCOMES. Table 3 presents safety out-
comes in the prohibitive-risk DMR cohort. Rates ofnonfatal events were consistent with the published
safety proﬁle for TMVR observed in the EVEREST II
High Risk Registry (2) and the ACCESS-EU Study
(ACCESS-Europe A Two-Phase Observational Study of
the MitraClip System in Europe) (6).
Eight patients died within 30 days of the TMVR
procedure. This observed 30-day mortality rate of
6.3% was considerably less than the study pop-
ulation’s mean STS-predicted surgical mortality of
CENTRAL ILLUSTRATION Impact of TMVR on MR and Reduction of HF Rehospitalization Rate
(A) From baseline to discharge and (B) from discharge to 1 year (n and % based on 127 [100%]). (C) Mitral regurgitation (MR) grade at
discharge and with deaths treated as heart failure (HF) hospitalizations.
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18613.2% with SMVR. Through 12 months, there were a
total of 30 deaths (23.6%).
The median age of patients who died prior to 30
days was 86 years; 3 were female and 5 were male.
Four (4) of the 8 patients received 2 devices, 2 pa-
tients received 1 device, and 2 patients did not
receive any TMVR. The mean predicted surgical
mortality risk of the 8 patients (using STS version
2.73 replacement score) was 17.6%. Six deaths were
clinical event committee–adjudicated as cardiac re-
lated, and 1 of these was further adjudicated as de-
vice related due to a prolonged procedure. Reasons
for the 8 deaths included septic shock (n ¼ 1),
existing comorbidities (n ¼ 2), gastrointestinal bleed
(n ¼ 1), renal failure and cardiac tamponade (n ¼ 1),
myocardial infarction (n ¼ 1), vascular bleeding
(n ¼ 1), and stroke (n ¼ 1).There have been no reports of a TMVR device
embolization or single leaﬂet device attachment in
the prohibitive-risk DMR cohort through the observed
follow-up (median: 1.47 years).
POST-PROCEDURAL STATUS AND LENGTH OF
HOSPITAL STAY. The mean post-procedure length of
stay in the intensive care unit was 1.4  1.8 days.
The average length of hospital stay was 2.9  3.1
days. Despite the elderly, highly comorbid nature of
this population, 88% of the prohibitive-risk DMR
patients were discharged home following the TMVR
procedure.
MR SEVERITY. Central Illustration, panel A, shows MR
severity at baseline and discharge in patients with
paired measurements available (patients in the
REALISM continued-access registry were permitted
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FIGURE 1 SF-36 QoL Measures Through 1 Year
There were signiﬁcant improvements in the SF-36 quality of life questionnaire
results on both physical and mental components above the minimal clinically
important difference. MCID ¼ minimal clinically important difference; SF-36
QoL ¼ quality of life as measured using the 36-item Short Form Health
Survey.
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187to enroll based on site-determined MR severity,
which underwent subsequent ECL assessment.
Improvements to MR #2þ were observed in 62 of the
72 (86.1%) patients with baseline MR of 3þ and in
26 of the 38 (68.4%) patients with baseline 4þ MR.
Improvements to MR #1þ were observed in 42 of
the 72 (58.3%) patients with baseline MR of 3þ and
in 14 of the 38 (36.8%) patients with baseline
MR of 4þ.
Central Illustration, panel B, shows MR severity at
discharge and 1 year in patients with paired mea-
surements. Of 91 patients discharged with MR #2þ,
64 patients (70.3%) sustained MR #2þ at 1 year, 10
(11.0%) experienced worsening MR to 3þ or 4þ, and
17 (18.7%) died. Of 59 patients discharged with
MR #1þ, 21 patients (35.6%) sustained MR #1þ at
1 year, 20 (33.9%) experienced MR increase to 2þ, 8
(13.6%) experienced worsening MR to 3þ or 4þ, and
10 (16.9%) died.
CONVERSION TO OPEN MITRAL SURGERY IN
SURVIVING PATIENTS. Despite their high surgical
risk, 3 patients (2.4%) underwent open MV surgery
through 12 months following the TMVR procedure.
One patient who received 2 TMVR but did not ach-
ieve adequate MR reduction; this patient underwent
successful MV replacement 2 days post TMVR pro-
cedure and was alive at 1 year, with core-lab–rated
MR 1þ. The second patient who received 2 devices
but experienced continued HF after discharge; this
patient underwent successful MV replacement 56
days post TMVR and was alive at 1 year, with core-
lab–rated MR 1þ. The third patient underwent the
TMVR but did not receive a device due to leaﬂet pa-
thology; this patient underwent successful MV repair
26 days post TMVR but died of congestive HF 84 days
after surgery.
SF-36 QOL MEASURES. Figure 1 shows the SF-36
QoL PCS and MCS mean scores at baseline and
through follow-up. Mean scores, in particular for
PCS, were markedly depressed at baseline, but ap-
proximated population norms for adults who are
$75 years of age at 1, 6, and 12 months post TMVR.
Group changes from baseline, based on available
paired comparisons at each time point for the SF-36
summary scores as well as the 8 SF-36 subscales, are
shown in Table 4. The PCS scores at each follow-up
time point improved by w6 points from baseline,
and the MCS scores improved by w3 points at 30
days and 5 to 6 points thereafter (p < 0.01 for all
comparisons). These changes exceeded the 2- to
3-point threshold generally considered to indicate a
minimum clinically important difference (5). Highly
signiﬁcant improvements were seen for all SF-36subscales at every time point, except bodily pain
(which is not a typical manifestation of MR) and the
role-emotional scale at 30 days.
RELATIONSHIP OF ONGOING RESIDUAL MR TO
SURVIVAL. The relationship of residual MR to sur-
vival is shown in Figure 2. Notably, patients who were
discharged with MR severity of 2þ had survival 12-
month survival as those with MR #1þ at discharge. In
contrast, patients with either MR #1þ or 2þ at
discharge exhibited better 12-month survival than
those discharged with MR 3þ/4. Of the 22 patients
discharged with MR 3þ or 4þ, survival at 1 year was
52.4% (95% CI: 28.6% to 71.6%). Similarly, survival at
12 months was 83.3% (95% CI: 70.9% to 90.8%)
for patients discharged with MR #1þ and 80.0%
TABLE 4 SF-36 QoL Scores at Baseline and Changes From Baseline
(n ¼ 122 Evaluable Patients)
Item/Time Point
QoL Score D vs. Baseline*
Mean  SD (n) 95% CI Mean 95% CI p Value
Physical summary
Baseline 32.0  8.7 (121) (30.4 to 33.6) – – –
30 days 38.7  10.3 (101) (36.6 to 40.7) 6.2 (4.3 to 8.2) <0.0001
6 months 39.9  10.4 (66) (37.4 to 42.5) 5.9 (3.4 to 8.3) <0.0001
12 months 39.2  10.5 (76) (36.8 to 41.6) 6.0 (4.0 to 8.0) <0.0001
Physical function
Baseline 30.9  23.9 (122) (26.6 to 35.2) – – –
30 days 47.2  27.1 (103) (41.9 to 52.5) 15.7 (10.1 to 21.3) <0.0001
6 months 52.4  25.5 (67) (46.2 to 58.7) 15.1 (8.9 to 21.3) <0.0001
12 months 51.8  25.2 (76) (46.0 to 57.5) 16.6 (11.0 to 22.3) <0.0001
Role physical
Baseline 28.0  24.7 (122) (23.6 to 32.4) – – –
30 days 47.0  28.3 (101) (41.4 to 52.6) 18.5 (12.2 to 24.7) <0.0001
6 months 55.5  30.5 (68) (48.1 to 62.9) 25.2 (16.6 to 33.9) <0.0001
12 months 55.2  29.4 (76) (48.5 to 62.0) 24.4 (16.7 to 32.1) <0.0001
Bodily pain
Baseline 61.8  30.6 (122) (56.3 to 67.3) – – –
30 days 68.1  30.5 (102) (62.1 to 74.1) 5.9 (0.7 to 11.2) 0.0279
6 months 67.1  28.1 (66) (60.2 to 74.0) 3.8 (–3.5 to 11.2) 0.2994
12 months 64.6  29.8 (76) (57.8 to 71.4) 2.5 (–3.5 to 8.5) 0.4108
General health
Baseline 50.3  19.1 (122) (46.9 to 53.8) – – –
30 days 62.5  20.3 (103) (58.5 to 66.5) 11.2 (7.5 to 15.0) <0.0001
6 months 65.4  21.2 (69) (60.3 to 70.5) 12.5 (7.8 to 17.2) <0.0001
12 months 61.3  21.0 (76) (56.5 to 66.1) 9.3 (4.7 to 14.0) 0.0001
Mental summary
Baseline 46.1  12.5 (121) (43.9 to 48.4) – – –
30 days 49.5  11.3 (101) (47.3 to 51.8) 3.4 (1.0 to 5.9) 0.0064
6 months 52.7  9.7 (68) (50.3 to 55.0) 6.1 (2.9 to 9.3) 0.0004
12 months 51.8  10.5 (76) (49.4 to 54.2) 5.6 (2.3 to 8.9) 0.0011
Vitality
Baseline 37.5  21.9 (121) (33.6 to 41.4) – – –
30 days 52.3  23.3 (102) (47.7 to 56.8) 14.0 (8.8 to 19.2) <0.0001
6 months 54.3  20.5 (69) (49.4 to 59.2) 13.8 (7.1 to 20.5) 0.0001
12 months 54.9  20.1 (76) (50.3 to 59.5) 16.4 (10.5 to 22.4) 0.0001
Social function
Baseline 53.2  31.1 (122) (47.6 to 58.8) – – –
30 days 68.8  27.8 (102) (63.3 to 74.2) 16.7 (10.1 to 23.3) <0.0001
6 months 76.8  24.2 (69) (71.0 to 82.6) 21.7 (14.0 to 29.4) <0.0001
12 months 75.0  27.8 (76) (68.7 to 81.3) 19.9 (11.9 to 27.9) <0.0001
Role emotional
Baseline 63.3  35.1 (122) (57.0 to 69.6) – – –
30 days 69.3  31.5 (100) (63.1 to 75.6) 4.1 (–2.7 to 11.0) 0.2342
6 months 78.4  25.6 (68) (72.2 to 84.6) 14.1 (5.1 to 23.0) 0.0025
12 months 74.3  29.3 (76) (67.6 to 81.0) 10.4 (1.4 to 19.4) 0.0246
Mental health index
Baseline 70.9  19.7 (121) (67.3 to 74.4) – – –
30 days 76.5  18.4 (102) (72.9 to 80.1) 5.6 (2.0 to 9.3) 0.0028
6 months 79.0  16.1 (69) (75.2 to 82.9) 7.1 (2.7 to 11.5) 0.0021
12 months 79.4  16.8 (76) (75.6 to 83.2) 8.0 (3.4 to 12.6) 0.0008
Only patients in the high-risk arm of the REALISM (Real World Expanded Multi-center Study of the MitraClip
System) continued-access registry completed SF-36 QoL (36-item Short Form Health Survey) questionnaires at
6 months. *Reported for patients with paired measurements at baseline and follow-up.
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188(95% CI: 62.2% to 90.1%) for patients discharged with
MR 2þ.
HF HOSPITALIZATIONS. HF hospitalizations 12
months prior to and 12 months following the
MitraClip procedures were recorded and analyzed.
Length of follow-up post TMVR was adjusted for in
the analysis. As shown in Figure 3A, a signiﬁcant
decrease in the rate of hospitalization for HF was
observed following discharge after TMVR, from
0.67 (95% CI: 0.54 to 0.83) to 0.18 (95% CI: 0.11 to
0.28) per patient-year, a 73% reduction. When death
was treated as a HF hospitalization in a sensitivity
analysis, the HF hospitalization rate was still
signiﬁcantly reduced, from 0.67 (95% CI: 0.54 to
0.83) to 0.44 (95% CI: 0.33 to 0.60) per patient-year,
as shown in Figure 3B. In contrast, as shown in the
Central Illustration (panel C), patients with ongoing
or untreated severe MR at discharge had no reduc-
tion in the rate of HF hospitalization or death
following TMVR.
NYHA FUNCTIONAL CLASS. Figure 4A shows NYHA
functional class at baseline and 30 days for patients
with paired data available. Improvements to NYHA
functional class I or II were observed in 60 of 79 pa-
tients (75.9%) with baseline class III and in 17 of 26
patients (65.3%) with baseline class IV. Figure 4B
shows NYHA functional class at baseline and 1 year
for patients with paired data available. Of 98 patients
with baseline NYHA functional class III/IV, 30 (30.6%)
patients experienced an improvement of at least 2
classes.
Reduction of MR to #2þ at discharge was associ-
ated with a higher probability of being alive with
NYHA functional class I/II at 1 year (71.7% of patients
discharged with MR #1þ, 69.7% of patients dis-
charged with MR ¼ 2þ, and 36.8% of patients dis-
charged with MR 3þ or 4þ) compared with continued
or untreated severe MR at discharge. There was no
statistically signiﬁcant difference in the probability of
NYHA class I/II at 1 year between the discharge
MR #1þ and MR ¼ 2þ groups. Additionally, the
probabilities of NYHA class I/II at 1 year in the MR #1þ
and MR ¼ 2þ groups were signiﬁcantly different than
in the MR 3þ/4þ group (p ¼ 0.013 and 0.044,
respectively).
LV FUNCTION. Compared with baseline, LV end-
diastolic volume decreased signiﬁcantly, from 125.1
 40.1 ml to 108.5  37.9 ml at 12 months (p < 0.0001)
in survivors with paired data (n ¼ 69). LV end-systolic
volume decreased from 49.1  24.5 ml to 46.1  21.4
ml at 12 months (p ¼ 0.07) in survivors with paired
data (n ¼ 69).
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FIGURE 2 Kaplan-Meier Survival Curves by Discharge MR Severity (#1þ, 2þ, 3þ/4þ)
p values unadjusted for baseline differences in comorbidities. Stratiﬁcation of patients by residual MR severity is demonstrated as it pertains
to event-free survival. MR ¼ mitral regurgitation.
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189DISCUSSION
This is the ﬁrst report on the use of the TMVR
device speciﬁcally in patients with DMR considered
at prohibitive risk for MV surgery. In this popula-
tion, as in others, TMVR had a high initial success
rate (95%) with a low rate of serious complications,
30-day mortality, and subsequent MV surgery. A
large majority of these patients achieved reduction
in their MR to 2þ or less, and this was associated
with improvements in NYHA functional class and
QoL, reductions in HF hospitalization, and LV
reverse remodeling. In addition, patients with 2þ
residual MR at discharge were found to have similar
survival rates to those with #1þ MR, withboth having better survival than patients with 3þ/
4þ MR at discharge.
Since TMVR with the MitraClip was ﬁrst described
by St. Goar et al. (7), there has been signiﬁcant in-
terest in the potential of this less invasive therapy.
Patients who initially received this novel therapy in
the United States were randomized against gold-
standard MV surgery in the EVEREST II trial and
thus comprised a relatively low-risk and predomi-
nantly degenerative etiology population who were
shown to have more complete MR reduction with
surgery than the percutaneous method. However,
given the results of the EVEREST II trial in patients too
high risk for surgery (High Risk Registry and REALISM
high risk), it has become clear that the initial clinical
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FIGURE 3 Reduction in HF Hospitalizations
(A) 1 year prior to TMVR and 1 year post-discharge, and (B) with deaths treated as heart failure (HF) hospitalizations.
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190role for this percutaneous valve repair technology lies
with patients at prohibitive risk for open SMVR of
their degenerative (primary) MR.
Over time, the description of patients at signiﬁcant
operative risk for open MV repair has changed, but
the concept remains the same. The term prohibitive
risk was deﬁned as those patients with a predictedBaseline
5 (3.9%) withdrawals or missing data not shown in line plot above:
1 (0.8%) Class III at BL withdrew prior to 30 days
1 (0.8%) Class III at BL missing NYHA measurement at 30 days
3 (2.4%) Class IV at BL missing NYHA measurement at 30 days
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FIGURE 4 Change in NYHA Functional Class
(A) From baseline to 30 days and (B) from baseline to 1 year (n and %risk of mortality for open MV replacement of $8%
based on the STS risk calculator, or by considering
other serious comorbidities shown to be associated
with high risk that are not taken into account in the
STS risk calculator. Notably, only 5% of all isolated
MV surgeries in the STS database had a score $8%,
and 85% of those underwent MV replacement (dataBaseline
13 (10.2%) withdrawals or missing data not shown in line plot above:
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based on 127 [100%]).
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191on ﬁle from a query of the STS database conducted in
December 2012 of all isolated MV surgeries between
2008 and 2012, Abbott Vascular). Prohibitive risk does
not imply “inoperable,” but rather that the risk of
open surgery signiﬁcantly outweighs the usual ex-
pected beneﬁt. A similar deﬁnition of risk was used in
the EVEREST High Risk study (2).
The increased operative risk is related not to the
patients’ MV disease but rather to the person “wrap-
ped around” the regurgitant valve. Despite their risk,
the procedural outcomes were favorable, with no
intraprocedural deaths, few device related complica-
tions, safety results not worse than for surgery in the
lower-risk randomized trial, a procedure time of
approximately 2.5 h on average, and a procedure
success rate of more than 95%. In terms of resource
utilization, it is impressive that, in this elderly pop-
ulation with multiple comorbidities, the hospital
length of stay following TMVR was approximately 3
days, with nearly 90% of patients discharged to their
homes. These resource patterns suggest that TMVR
may be less expensive than MV surgery would be for
similar patients (8).
One of the points of concern that has been raised
previously in comparison to open SMVR is that
TMVR achieves a lesser degree of MR reduction. In
this prohibitive-risk cohort of patients, nearly 80%
of patients with MR 3þ or 4þ at baseline achieved a
MR reduction to #2þ at time of discharge. Were
these patients at lower operative risk, it is likely that
highly experienced MV surgeons could have ach-
ieved a lower residual MR in a greater proportion of
patients. Despite this lesser degree of MR reduction,
the results with TMVR in this population are stable
over time, with more than 85% of survivors main-
taining their MR reduction of #2þ at 1-year follow-
up. The reduction in MR has been durable to 4
years’ follow-up in the EVEREST II RCT (9).
Given that these prohibitive-risk patients have no
other medical or surgical option, the expectation of
clinical beneﬁt from the procedure has been met in
the majority.
This procedural beneﬁt clearly has translated to
clinical beneﬁts as evidenced by improvement in
functional status and QoL. These changes were
statistically robust and clinically meaningful. The
mean changes in SF-36 summary scales following
TMVR in this population were not only well above
established thresholds, but in fact returned the group
means to previously reported age-adjusted norms.
The ﬁnding of improved LV function is consistent
with the expected reduced pre-load as a result of the
reduction in MR severity achieved with the TMVRdevice and provides a physiologic basis for the
observed functional improvements.
Importantly, this study did not ﬁnd a marked dif-
ference in patient outcomes between the groups with
1þ residual MR versus those with 2þ residual MR. In
both cases, there were signiﬁcant improvements
compared with those with 3þ or 4þ residual MR. It is
likely that for such a high-risk comorbid cohort, being
able to achieve MR reduction to below surgical
referral standards without the biologic cost of a more
invasive approach is a success on the individual
level.
STUDY LIMITATIONS. These data encompass the
early experience with TMVR and are thus limited by
relative inexperience of the individual TMVR oper-
ators in the United States. These data also were
limited by the lack of randomization, because
medical therapy, does not have a treatment role for
DMR and surgical options were prohibitive, so a
control arm was not possible. Because the
cohort was retrospectively identiﬁed, all analyses
were post-hoc. Another limitation is that follow-up
echocardiographic and functional data were ob-
tained and reported for surviving patients only. No
imputation for deceased patients’ data was per-
formed, although deaths and missing data were
reported.
CONCLUSIONS
The TMVR device is safe in patients with severe
degenerative (primary) MR for whom a heart team has
determined that MV surgery is associated with a
prohibitive risk/beneﬁt ratio. Transcatheter reduction
of DMR in these patients provides signiﬁcant beneﬁts,
including improvements in symptoms and functional
status, a decrease in hospitalizations, and favorable
LV remodeling at 1 year.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: For pa-
tients with severe, DMR, valve repair surgery in an
experienced center effectively addresses the intrinsic
valvular abnormality more effectively than medical ther-
apy alone.
COMPETENCY IN PATIENT CARE: Transcatheter
deployment of the MitraClip device may be considered
for patients with severe DMR who would face a prohibi-
tive risk of morbidity or mortality related to valve
surgery.
TRANSLATIONAL OUTLOOK 1: More information
about clinical outcomes of the MitraClip procedure in
patients with functional MR secondary to cardiomyopathy
rather than intrinsic valvular pathology is needed from
ongoing randomized trials.
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